RSS | Login | Register

CELEBREX

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare CELEBREX to:

Generic Name for CELEBREX

Celecoxib 50mg, 100mg, 200mg, 400mg; caps.

Legal Classification:

Pharmacological Class for CELEBREX

NSAID (COX-2 inhibitor).

Manufacturer of CELEBREX

Pfizer Labs

Indications for CELEBREX

Acute pain.

Adult dose for CELEBREX

≥18yrs: 400mg once then 200mg more on 1^st day if needed, then 200mg twice daily. <50kg: start at lowest recommended dose.

Children's dosing for CELEBREX

Not recommended.

Contraindications for CELEBREX

Sulfonamide or aspirin allergy. 3^rd trimester pregnancy. Coronary artery bypass graft surgery.

Warnings/Precautions for CELEBREX

Advanced renal disease or severe hepatic impairment: not recommended. Renal or liver dysfunction; reduce dose by 50% in moderate hepatic insufficiency (Child-Pugh class B). Discontinue if liver disease or systemic effects (eg, eosinophilia, rash) develops. History or risk of GI bleed/ulcer (monitor). Fluid retention. Heart failure. Hypertension. Asthma. Alcoholism. Dehydrated. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for CELEBREX

Caution with drugs that inhibit CYP2C9 (eg, fluconazole) or are metabolized by CYP2D6. May antagonize, or increase risk of renal failure with ACEIs, diuretics. Increased risk of GI bleed with aspirin (except low-dose), corticosteroids, smoking, anticoagulants. May potentiate lithium. Monitor warfarin.

Adverse Reactions for CELEBREX

GI upset/pain, edema, pharyngitis, increase AST/ALT, GI ulcer/bleed; rare: intracranial bleed, liver failure. See literature re: risk of cardiovascular events.

How is CELEBREX supplied?

Caps 100mg, 200mg—100, 500
50mg, 400mg—60

Related Disease:

Pain, general~nonnarcotics

Phase 2 study of SB-509 for diabetic neuropathy (DN)

July 01, 2010

Sangamo BioSciences announced positive Phase 2 data from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy (DN).

McNeil Consumer Healthcare product supply update

June 25, 2010

McNeil Consumer Healthcare announced that it does not anticipate having sources of supply for most of the products that were produced at its Fort Washington, Pennsylvania manufacturing facility before the end of 2010.

Rybix ODT launched for moderate to moderately severe pain

June 18, 2010

Victory Pharma announced that it has launched Rybix ODT (tramadol HCl, orally disintegrating tablets) for the management of moderate to moderately severe pain in patients ≥16 years of age.

McNeil recalls Benadryl Allergy Ultratab and Extra Strength Tylenol Rapid Release Gels

June 16, 2010

McNeil Consumer Healthcare has expanded its January 15, 2010 recall to include four lots of Benadryl Allergy (diphenhydramine) Ultratab Tablets and one lot of Extra Strength Tylenol (acetaminophen) Rapid Release Gels.

CDC issues statement and recommendations regarding prescription drug misuse

June 04, 2010

The CDC announced the 2009 National Youth Risk Behavior Survey (YRBS) found that 1 in 5 high school students have ever taken a prescription drug such as OxyContin (oxycodone, from Purdue), Percocet (oxycodone/acetaminophen, from Endo), Vicodin (hydrocodone/acetaminophen, from Abbott), Adderall (mixed salts of a single-entity amphetamine product, from Shire), Ritalin (methylphenidate, from Novartis), or Xanax (alprazolam, from Pfizer), without a prescription.